Observational studyThe Journal of infection2021
Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France.
Observational study in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review.Journal of infection and public health · 2023Pooled it
- Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- Epidemiology of Urinary Pathogens and Antibiotic Resistance Trends: A Retrospective Analysis Stratified by Age and Sex from a Large Tertiary Hospital in Saudi Arabia.Infection and drug resistance · 2026Article
- Exploring multidrug resistance patterns in community-acquiredAntimicrobial agents and chemotherapy · 2025Article
- COVID-19 impact on AMR: a rapid scoping review, equity analysis and evidence gap map study.BMJ global health · 2025Article
- Associations between antibiotic consumption intensity and extended-spectrum cephalosporin resistance in nursing homes: a retrospective ecological study.JAC-antimicrobial resistance · 2025Article
- Detection of O25B-ST131 clone andPeerJ · 2025Article
- The challenge of multidrug resistance in hospitalized pediatric patients with urinary tract infections.Frontiers in cellular and infection microbiology · 2025Article
- Rebound of Antibiotic Use and Respiratory Infections After Resumption of Normalcy From COVID-19 in Hong Kong.Infection and drug resistance · 2025Article
- Impact of the COVID-19 pandemic on extended-spectrum β-lactamase producing Escherichia coli in urinary tract and blood stream infections: results from a nationwide surveillance network, Finland, 2018 to 2022.Antimicrobial resistance and infection control · 2024Article
- Distribution and molecular characterization of carbapenemase-producing gram-negative bacteria in Henan, China.Scientific reports · 2024Article
- Wild-Type AmpC Beta-Lactamase-ProducingDiseases (Basel, Switzerland) · 2024Article
- Post-Coronavirus Disease 2019 Pandemic Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2024Article
- Extended-spectrum β-lactamase- producing gram-negative bacterial infections in severely ill COVID-19 patients admitted in a national referral hospital, Kenya.Annals of clinical microbiology and antimicrobials · 2023Article
- Distribution and Drug Resistance of Bacterial Infection in Hospitalized Patients at the Respiratory Department before and after the COVID-19 Pandemic in Guangzhou, China.Microorganisms · 2023Article
- Impact of the COVID-19 pandemic on community antibiotic consumption in the EU/European Economic Area: a changepoint analysis.The Journal of antimicrobial chemotherapy · 2023Article
- Leveraging the COVID-19 pandemic as a natural experiment to assess changes in antibiotic use and antibiotic-resistant E. coli carriage in semi-rural Ecuador.Scientific reports · 2023Observational
- Impact of the COVID-19 Pandemic on Epidemiology of Antibiotic Resistance in an Intensive Care Unit (ICU): The Experience of a North-West Italian Center.Antibiotics (Basel, Switzerland) · 2023Article
- The Impact of COVID-19 Pandemic on ESBL-ProducingAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe investigated the impact of the COVID-19 and national pandemic response on the epidemiology of Extended Spectrum Beta-Lactamase producing E. coli (ESBL-E.coli) in France.
methodsIndividual microbiology records from clinical laboratories were analyzed between 1 January 2019 to 31 December 2020. The ESBL-E.coli rates from clinical samples of patients in primary care and nursing home residents were compared before and after the general lockdown in March 2020, according to demographic and geographical characteristics. Interrupted time series analyses were performed to detect measurable changes in the trend of ESBL-E.coli rates.
resultsRecords covering 793,954 E. coli isolates from 1022 clinical laboratories were analyzed. In primary care, 3.1% of E. coli isolates from clinical samples were producing ESBL before March 2020 and 2.9% since May 2020 (p < 0.001). The proportion of ESBL-E.coli decreased significantly among urine cultures, females, age categories 5-19, 40-64, > 65 year-old, and in the North, West, East and South-East regions. In nursing home, the ESBL-E.coli rate was 9.3% (monthly rate min-max: 6.5-10.5%) before March 2020 and 8.3% (7.2-9.1%) since May 2020 (p < 0.001). The reduction rate accelerated from -0.04%/month to -0.22%/month from May 2020 (p < 0.001).
conclusionInvestigation of factors that led to the decreased proportion of ESBL-E.coli during the COVID-19 pandemic is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.